FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1066-1067 October 4, 2001 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: In their review, Mannucci and Tuddenham (June 7 issue)¹ discuss the use of recombinant clotting factors for the treatment of hemophilia. When these products were introduced, it was anticipated that there would be an inexhaustible supply of the "safe" factors. Scientific and lay leaders of the National Hemophilia Foundation and the World Federation of Hemophilia heralded these products as optimal therapy.

Because it has long been known that viral diseases may be transmitted from person to person, human-derived blood products have been considered to be less than perfectly safe. Since the introduction of viral-inactivated human-derived products, however, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Ghosh, N., Marotta, P. J., McAlister, V. C. (2005). Correction of Factor XI Deficiency by Liver Transplantation. NEJM 352: 2357-2358 [Full Text]